In the subgroups analysis, including age ≥ 70 or < 70 years, with or without diabetes mellitus, with or without heart failure, with or without hypertension, with or without ACEI/ARB use, or CKD stage ≥3 or < 3, the change in eGFR between 2-year eGFR and baseline eGFR did not differ among dabigatran, warfarin, and anti-factor Xa inhibitor groups (Supplemental Fig. 2). This evidence concerns the gene F10 and chronic kidney disease.